COST-EFFECTIVENESS ANALYSIS OF HEPATITIS-B VACCINATION STRATEGIES IN CATALONIA, SPAIN

被引:13
作者
ANTONANZAS, F [1 ]
GARUZ, R [1 ]
ROVIRA, J [1 ]
ANTON, F [1 ]
TRINXET, C [1 ]
NAVAS, E [1 ]
SALLERAS, L [1 ]
机构
[1] UNIV LA RIOJA,DEPT ECON,LOGRONO,SPAIN
关键词
D O I
10.2165/00019053-199507050-00007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Hepatitis B virus (HBV) infection is an important public health problem all over the world. Vaccination is one way to prevent it, and several strategies can be used depending on endemicity, the main pattern of HBV transmission and the demographic structure of the population. In this study, an economic comparison of 3 vaccination strategies (mass adolescent vaccination, mass infant vaccination and mass combined vaccination) was performed in Catalonia, Spain. Screening pregnant women for HBV infection in combination with these strategies was also evaluated. Epidemiological models to analyse patterns of HBV infection with and without vaccination and to calculate HBV-associated costs were designed. Comparison between strategies was done using cost-effectiveness analysis from the perspective of the healthcare system. Epidemiological model results indicate that implementation of HBV vaccination could prevent as many as 104 778 new acute infections, and avoid up to 5239 chronic infections, 2096 cases of cirrhosis and 419 cases of hepatocarcinoma over a 20-year period in Catalonia. Cost-effectiveness analysis shows that mass adolescent vaccination is the most efficient strategy, with lower costs per avoided case than the other 2 strategies. When any of these strategies is complemented by screening for HBV in pregnant women, the number of avoided cases is always higher and the cost per avoided case decreases or remains unchanged.
引用
收藏
页码:428 / 443
页数:16
相关论文
共 32 条
  • [1] Holliday S., Faulds D., Hepatitis B vaccine a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection, Pharmacoeconomics, 5, 2, (1994)
  • [2] Vyas G.N., Blum H.E., Hepatitis B virus infection-current Concepts of chronicity and immunity, West J Med, 140, (1984)
  • [3] Sherlock S., Virus hepatitis B, A, non-A, non-B, J Hepatol, 8, (1989)
  • [4] MMWR Morb Mortal Wkly Rep, 40, 13 RR, (1991)
  • [5] Bruguera M., Sanchez J.M., Epidemiología de la hepatitis B en España, Med Clin (Barc), 95, (1990)
  • [6] Kiire C.F., Hepatitis B infection in sub-Saharan Africa: the African Regional Study Group, Vaccine, (1990)
  • [7] Salleras L., Bruguera M., Vidal J., Et al., Prevalence of hepatitis B markers in the population of Catalonia (Spain): rationale for universal vaccination of adolescents, Eur J Epidemiol, 8, (1992)
  • [8] Sherlock S., Hepatitis B: the disease, Vaccine, (1990)
  • [9] Brugucra M., ¿Cömo y a quién vacunar contra la hepatitis B en España?, J Med Clin (Barc), 82, (1984)
  • [10] Bruguera M., La vacunaciön contra la hepatitis B: un objetivo prioritario, Jano, 37, (1989)